Cosentyx under Real-World watch for kids and adults with skin and joint disease

NCT ID NCT07243782

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tracks the safety and effectiveness of the drug Cosentyx (secukinumab) in Korean patients with hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis. Researchers will monitor 76 participants for side effects and how well the drug works in real-world use. The goal is to ensure the drug remains safe and effective after it has been approved for these conditions.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Secukinumab (Cosentyx)
What this could lead to
If successful, this study will confirm that Cosentyx is safe and effective for treating these skin and joint conditions in Korean patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like infections or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06973, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.